AL-S Pharma Reports AP-101 Weight Data, Outlines ALS Phase 3 Trial
AL-S Pharma reported new Phase 2 post-hoc weight data for AP-101 and outlined a Phase 3 clinical trial in ALS at the 2026 NEALS Annual Meeting.
AL-S Pharma reported new Phase 2 post-hoc weight data for AP-101 and outlined a Phase 3 clinical trial in ALS at the 2026 NEALS Annual Meeting.